The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41802050.
- Also identified by DOI 10.1073/pnas.2525730123 and PMC identifier 12994185.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The loss of major histocompatibility complex class I (MHC-I) molecules has been proposed as a mechanism for cancer immune evasion. Nevertheless, the mechanism is poorly understood. We report here that membrane-associated RING-CH-type finger 8 (MARCHF8), upregulated by human papillomavirus (HPV), ubiquitinates and degrades MHC-I in HPV-positive head and neck cancer (HPV+ HNC). Inhibiting MARCHF8 restores MHC-I levels on HPV+ HNC cells, suppresses tumor growth, and increases the infiltration of natural killer (NK) and T cells in the tumor microenvironment. Furthermore, <i>Marchf8</i> knockout markedly increases cross talk between cytotoxic NK cells and CD8<sup>+</sup> T cells with macrophages and enhances the tumor-killing activity of CD8<sup>+</sup> T cells. Interestingly, <i>Marchf8</i> knockout, in combination with anti-PD-1 treatment, further enhances tumor suppression and increases NK and T cell infiltration in mice bearing immune checkpoint inhibitor-refractory tumors. Our findings suggest that MARCHF8 could be a promising target for immunotherapy for HPV+ HNC patients.
Medical subject headings
- Ubiquitin-Protein Ligases
- Histocompatibility Antigens Class I
- Head and Neck Neoplasms
- Papillomavirus Infections
- Immune Evasion
- Membrane Proteins
- Tumor Escape